| pubmed-article:12239449 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0334246 | lld:lifeskim |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:12239449 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:12239449 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12239449 | pubmed:dateCreated | 2002-9-19 | lld:pubmed |
| pubmed-article:12239449 | pubmed:abstractText | Since the combination of cisplatin and docetaxel have demonstrated activity in squamous cell carcinomas of the lung and oesophagus before, promising results in recurrent metastatic head and neck cancer were expected. | lld:pubmed |
| pubmed-article:12239449 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12239449 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12239449 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12239449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12239449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12239449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12239449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12239449 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12239449 | pubmed:issn | 0030-2414 | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:FormanekMM | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:MarksBB | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:SelzerEE | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:KornekG VGV | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:BurianMM | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:CartellieriMM | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:KornfehlJJ | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:FiebigerWW | lld:pubmed |
| pubmed-article:12239449 | pubmed:author | pubmed-author:GedlickaCC | lld:pubmed |
| pubmed-article:12239449 | pubmed:copyrightInfo | Copyright 2002 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:12239449 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12239449 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:12239449 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12239449 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12239449 | pubmed:pagination | 145-50 | lld:pubmed |
| pubmed-article:12239449 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:meshHeading | pubmed-meshheading:12239449... | lld:pubmed |
| pubmed-article:12239449 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12239449 | pubmed:articleTitle | Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. | lld:pubmed |
| pubmed-article:12239449 | pubmed:affiliation | Department of Internal Medicine I, Division of Oncology, University of Vienna, Vienna, Austria. | lld:pubmed |
| pubmed-article:12239449 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12239449 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12239449 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12239449 | lld:pubmed |
